Quarterly ResultMay 14, 2026, 08:07 AM
Candel Therapeutics Plans Q4 2026 BLA for Prostate Cancer; Q1 Net Loss $8.9M
AI Summary
Candel Therapeutics announced its Q1 2026 financial results and provided a corporate update, highlighting plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026. The company also established a commercial partnership with EVERSANA for a potential U.S. launch and plans to initiate a pivotal Phase 3 clinical trial for aglatimagene in NSCLC in Q2 2026. Financially, Candel reported a net loss of $8.9 million for Q1 2026, but ended the quarter with $194.8 million in cash, expected to fund operations into Q1 2028.
Key Highlights
- Planned BLA submission for aglatimagene in localized prostate cancer in Q4 2026.
- Commercial partnership with EVERSANA to support potential U.S. launch of aglatimagene.
- Pivotal Phase 3 clinical trial for aglatimagene in NSCLC to initiate in June 2026.
- Q1 2026 Net Loss was $8.9 million, compared to Net Income of $7.4 million in Q1 2025.
- Research and development expenses increased to $9.8 million in Q1 2026 from $4.0 million YoY.
- Cash and cash equivalents of $194.8 million as of March 31, 2026, fund operations into Q1 2028.
- Raised $100 million gross proceeds from common stock issuance in February 2026.
- Secured $100 million royalty funding agreement with RTW, contingent on FDA approval.